Component
Plasma THC concentration
Plasma THC concentration. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The median area under the curve of THC was threefold higher and that of THC-COOH 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes, with a trend toward increased sedation, while CYP2C9*2 status made no difference.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- evidence_span
- {"source_cache": "artifacts/thc-research/19005461.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e", "start_char": 0, "end_char": 601, "text_sha256": "67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e"}
- experimental_model
- Oral THC in 43 healthy volunteers genotyped for CYP2C9
- exposure
- Oral THC across CYP2C9 genotypes
- limitations
- A pharmacogenetic study with a clear exposure difference. The sedation finding is described as a trend.
- nutrient_topic
- THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. · Delta-9-tetrahydrocannabinol / THC
- organism
- Human
- plain_language
- People with two copies of one variant get three times the drug exposure from the same dose.
- primary_references
- [thc-p19005461] Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (2009). https://pubmed.ncbi.nlm.nih.gov/19005461/ DOI: 10.1038/clpt.2008.213
- tissue_or_cell_type
- Whole body
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21) · lines 530–541
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Oral THC in 43 healthy volunteers genotyped for CYP2C9 · source_derived_draft · unverified_draft
### thc-cyp2c9-exposure The median area under the curve of THC was threefold higher and that of THC-COOH 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes, with a trend toward increased sedation, while CYP2C9*2 status made no difference. Condition category: machinery_impairment nutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. plain_language: People with two copies of one variant get three times the drug exposure from the same dose. organism: Human tissue_or_cell_type: Whole body experimental_model: Oral THC in 43 healthy volunteers genotyped for CYP2C9 limitations: A pharmacogenetic study with a clear exposure difference. The sedation finding is described as a trend. exposure: Oral THC across CYP2C9 genotypes evidence_span: {"source_cache": "artifacts/thc-research/19005461.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e", "start_char": 0, "end_char": 601, "text_sha256": "67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e"} [thc-p19005461] Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (2009). https://pubmed.ncbi.nlm.nih.gov/19005461/ DOI: 10.1038/clpt.2008.213
Complete structured claim and evidence
Where it participates (unsigned role)
Plasma cannabinoid pharmacokinetics following controlled oral THC and oromucosal cannabis extract administration resolved the time courses of THC and its metabolites.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/thc-research/21078841.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0ae96dadadcd8c1ee096e38d9a531fc9182b5670b97837d6d1ddad9cd611e2f9", "start_char": 0, "end_char": 1727, "text_sha256": "0ae96dadadcd8c1ee096e38d9a531fc9182b5670b97837d6d1ddad9cd611e2f9"}
- experimental_model
- Controlled oral THC and oromucosal cannabis extract with serial plasma sampling
- exposure
- Controlled oral THC and oromucosal extract dosing
- limitations
- A controlled human pharmacokinetic study with the metabolites measured. Oral and oromucosal routes only; it does not describe smoked exposure.
- nutrient_topic
- THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. · Delta-9-tetrahydrocannabinol / THC
- organism
- Human
- plain_language
- The drug is measured alongside the two metabolites it becomes.
- primary_references
- [thc-p21078841] Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. (2011). https://pubmed.ncbi.nlm.nih.gov/21078841/ DOI: 10.1373/clinchem.2010.152439
- tissue_or_cell_type
- Plasma
THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21) · lines 517–528
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Controlled oral THC and oromucosal cannabis extract with serial plasma sampling · source_derived_draft · unverified_draft
### thc-thc-metabolites Plasma cannabinoid pharmacokinetics following controlled oral THC and oromucosal cannabis extract administration resolved the time courses of THC and its metabolites. Condition category: normal nutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. plain_language: The drug is measured alongside the two metabolites it becomes. organism: Human tissue_or_cell_type: Plasma experimental_model: Controlled oral THC and oromucosal cannabis extract with serial plasma sampling limitations: A controlled human pharmacokinetic study with the metabolites measured. Oral and oromucosal routes only; it does not describe smoked exposure. exposure: Controlled oral THC and oromucosal extract dosing evidence_span: {"source_cache": "artifacts/thc-research/21078841.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0ae96dadadcd8c1ee096e38d9a531fc9182b5670b97837d6d1ddad9cd611e2f9", "start_char": 0, "end_char": 1727, "text_sha256": "0ae96dadadcd8c1ee096e38d9a531fc9182b5670b97837d6d1ddad9cd611e2f9"} [thc-p21078841] Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. (2011). https://pubmed.ncbi.nlm.nih.gov/21078841/ DOI: 10.1373/clinchem.2010.152439
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.